HMG-CoA synthase

HMG-CoA synthase exists in two isoforms with different cellular locations and metabolic roles. The cytosolic isoform is expressed in the liver and other tissues and functions in the early steps of cholesterol biosynthesis, converting acetyl-CoA and acetoacetyl-CoA into HMG-CoA, which is subsequently reduced by HMG-CoA reductase (the rate-limiting, statin-targeted step) to mevalonate. The mitochondrial isoform is primarily expressed in the liver and is essential for ketogenesis, particularly during states of fasting, starvation, or uncontrolled diabetes (diabetic ketoacidosis). In this pathway, HMG-CoA synthase converts acetoacetyl-CoA and acetyl-CoA (derived from beta-oxidation of fatty acids) into HMG-CoA, which is then cleaved by HMG-CoA lyase to form acetoacetate, a ketone body that can be further reduced to beta-hydroxybutyrate or spontaneously decarboxylated to acetone. Clinically, mitochondrial HMG-CoA synthase deficiency is a rare autosomal recessive disorder of fatty acid oxidation/ketogenesis that presents with hypoketotic hypoglycemia, often triggered by fasting or illness, and can mimic other fatty acid oxidation defects like MCAD deficiency. It is important to distinguish HMG-CoA synthase from HMG-CoA reductase: the former catalyzes an earlier, non-rate-limiting step (though critical for both pathways), while the latter is the rate-limiting enzyme of cholesterol synthesis targeted by statin drugs. Understanding this distinction is high-yield for boards, as questions may test the branch point between ketogenesis and cholesterol synthesis and the differential regulation of the two isoforms.